Lupin Introduces Prucalopride Tablets to the US Market – BW Healthcare
Lupin, a global pharmaceutical company, has announced the launch of Prucalopride tablets in the United States. Prucalopride is a serotonin receptor agonist used to treat chronic idiopathic constipation (CIC) in adults. The medication works by increasing the movement of stool through the intestines, helping to relieve symptoms of constipation such as infrequent bowel movements, hard or lumpy stools, and straining during bowel movements.
The launch of Prucalopride tablets in the U.S. marks a significant milestone for Lupin, as it expands the company’s presence in the gastroenterology market. Lupin’s Prucalopride tablets are available in 1mg and 2mg strengths, and are marketed under the brand name Motofen. The medication is approved by the U.S. Food and Drug Administration (FDA) for the treatment of CIC in adults.
Chronic idiopathic constipation is a common gastrointestinal disorder that affects millions of people in the United States. It is characterized by persistent Difficulty with bowel movements, and can have a significant impact on a person’s quality of life. Prucalopride has been shown to be effective in treating CIC, with clinical trials demonstrating significant improvements in bowel movement frequency and consistency.
The launch of Prucalopride tablets in the U.S. is a significant addition to the treatment options available for CIC patients. Lupin’s Motofen is a convenient and effective treatment option that can help patients manage their symptoms and improve their overall quality of life. The medication is available by prescription only, and patients should consult with their healthcare provider to determine the best course of treatment for their individual needs.
Lupin’s launch of Prucalopride tablets in the U.S. is part of the company’s ongoing commitment to expanding its portfolio of specialty medications. The company has a strong focus on developing and commercializing medications that address significant unmet medical needs, and the launch of Motofen is an important step forward in this effort.
Biocon Partners with NCSM to Enhance Accessibility of Affordable Biosimilars
Biocon Biologics Ltd, a global biosimilars company, has partnered with the National Cancer Society of Malaysia (NCSM) to launch a Patient Assistance Programme (PAP) aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia. The partnership combines Biocon’s expertise in biosimilars with NCSM’s community outreach to enhance cancer care accessibility and affordability in Malaysia. The program will initially provide Trastuzumab, a biosimilar, to cancer patients facing treatment delays due to budget constraints.
Under the partnership, Biocon Biologics will provide quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim, and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. The collaboration marks a meaningful step forward in expanding access to high-quality oncology biosimilars for cancer patients in need. Biocon Biologics aims to ease the treatment burden for underserved populations and strengthen Malaysia’s efforts to deliver inclusive, patient-centric healthcare.
The partnership is a significant step forward for Biocon Biologics, which has previously expanded access to diabetes care in Malaysia, serving over 345,000 patients. The company is now focusing on oncology through strategic partnerships like this one. The Memorandum of Understanding (MoU) was signed during the National Cancer Congress Malaysia 2025 event, emphasizing a commitment to improving patient-centric healthcare. Ratish Trehan, Head of Commercial, Emerging Markets, Biocon Biologics, and Dr Saunthari Somasundaram, NCSM President, signed the MoU in the presence of Health Minister Dzulkefly Ahmad.
NCSM is Malaysia’s first not-for-profit cancer organization, providing education, care, and support services. The organization has earned a strong reputation for fair practices and community trust, making it an ideal partner for Biocon Biologics’ PAP initiative in Malaysia. The partnership is expected to positively impact thousands of lives and contribute to Malaysia’s efforts to deliver inclusive, patient-centric healthcare. With this collaboration, Biocon Biologics and NCSM aim to make a meaningful difference in the lives of cancer patients in Malaysia, providing them with access to affordable, high-quality biosimilars and improving their overall quality of life.
My life as a fit father of four was turned upside down after receiving the Pfizer Covid vaccine, sparking a devastating chain of events that has cost me £100,000 in a desperate search for a cure.
Dean Valentine, a 59-year-old grandfather from Essex, claims that his life was turned upside down after receiving the Pfizer Covid vaccine in December 2021. Prior to the vaccine, Valentine was a healthy and active individual who enjoyed golfing, holidays, and spending time with his family. However, shortly after receiving the vaccine, he began to experience “devastating” and “bizarre” symptoms, including intense dizziness, full body tremors, and a permanent headache.
Despite seeking medical attention and trying various treatments, including private healthcare and health retreats, Valentine’s symptoms have persisted. He estimates that he has spent around £100,000 trying to find a cure, but to no avail. Valentine’s condition has left him a “shadow of the man he was,” and he feels like he is only 10% of his former self.
Valentine is certain that his symptoms are a result of the Covid vaccine, and he has been told the same by various professors and specialists. He is not seeking compensation, but rather wants to raise awareness about the potential risks of the vaccine and push for a medical pathway to be created for people who are suffering from similar symptoms.
Valentine’s story is not an isolated incident, as thousands of people have reported experiencing adverse reactions to the Covid vaccine. Recent studies have linked the vaccine to chronic conditions, including a previously unknown condition known as “post-vaccination syndrome,” which can cause brain fog, dizziness, and exercise intolerance.
Pfizer has stated that patient safety is paramount and that they take all reports of adverse events seriously. However, the company also notes that adverse event reports do not imply causality and that the benefit-risk profile of the vaccine remains positive for all authorized indications and age groups.
Valentine’s case highlights the need for further research into the potential risks and side effects of the Covid vaccine. He has raised over £25,000 through charity events to help people struggling with similar symptoms and is calling for a medical pathway to be created to support those affected. Valentine’s story is a heartbreaking reminder of the importance of prioritizing patient safety and ensuring that those who have been affected by the vaccine receive the help and support they need.
Pfizer obtains worldwide licensing rights, excluding China, for 3SBio’s innovative cancer treatment SSGJ-707, a dual-target therapy.
Pfizer has secured global licensing rights, excluding China, for 3SBio’s dual-target cancer therapy SSGJ-707. This agreement marks a significant collaboration between the two companies, with Pfizer gaining access to a promising new cancer treatment. SSGJ-707 is a novel, dual-targeting antibody-drug conjugate (ADC) that has shown potential in treating various types of cancer.
Under the terms of the agreement, Pfizer will be responsible for the development, manufacture, and commercialization of SSGJ-707 worldwide, except in China, where 3SBio will retain the rights. 3SBio will receive an upfront payment, as well as potential milestone payments and royalties on future sales.
SSGJ-707 is designed to target two specific proteins, CD19 and CD22, which are commonly expressed in certain types of cancer, including B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. The dual-targeting approach is intended to improve the efficacy and safety of the treatment, as well as reduce the risk of resistance.
The ADC technology used in SSGJ-707 involves linking a cytotoxic drug to a monoclonal antibody, which is designed to selectively target and kill cancer cells. This approach has shown promise in treating a range of cancer types, including hematological malignancies and solid tumors.
Pfizer’s acquisition of the global licensing rights for SSGJ-707 outside of China is a strategic move to strengthen its oncology portfolio. The company has been actively expanding its presence in the cancer treatment market, with a focus on innovative therapies that can improve patient outcomes.
The partnership with 3SBio is expected to accelerate the development of SSGJ-707, with Pfizer’s global resources and expertise enabling the therapy to reach a broader patient population. 3SBio, on the other hand, will benefit from Pfizer’s commercialization capabilities, while retaining the rights to the therapy in China.
This collaboration highlights the growing trend of partnerships between pharmaceutical companies and biotech firms, as they seek to leverage each other’s strengths to bring innovative treatments to market. The deal also underscores the increasing importance of China as a major player in the global biopharmaceutical industry, with companies like 3SBio emerging as key partners for international pharmaceutical companies. Overall, the licensing agreement between Pfizer and 3SBio has the potential to bring a promising new cancer therapy to patients worldwide, and marks an important step forward in the fight against cancer.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.